Literature DB >> 6737075

Radioimmunoassay of leukocyte (alpha) interferon and its application to some clinical conditions.

J Bernier, A Reuter, Y Vrindts-Gevaert, P Franchimont.   

Abstract

A radioimmunoassay for human leukocyte interferon alpha (alpha IFN) has been developed, using tracer produced by recombinant DNA (IFLrA) and polyclonal rabbit antiserum against partially purified leukocyte IFN (PP alpha IFN). Sensitivity was 4 units/ml using sequential saturation. Only lymphoblastoid IFN showed complete cross reactivity. Serum alpha IFN concentrations were measured in normal subjects and in patients with acute viral infections, bone and joint diseases, and malignancies. Some cases in the first two groups of patients had significantly elevated serum levels compared with controls. The pharmacokinetics of alpha IFN were studied in treated cancerous patients. Radioimmunoassay and biological assay gave similar and closely correlated results. Radioimmunoassay is thus a useful method for the routine assay of alpha IFN, especially in biological fluids containing low concentrations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6737075

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Interferon type I receptor-deficient mice have altered disease symptoms in response to influenza virus.

Authors:  Tim R Traynor; Jeannine A Majde; Stewart G Bohnet; James M Krueger
Journal:  Brain Behav Immun       Date:  2006-11-13       Impact factor: 7.217

2.  Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

Authors:  M Y Gordon; S B Marley; J L Lewis; R J Davidson; D X Nguyen; F H Grand; T A Amos; J M Goldman
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

3.  The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha.

Authors:  K S Khabar; F Al-Zoghaibi; M N Al-Ahdal; T Murayama; M Dhalla; N Mukaida; M Taha; S T Al-Sedairy; Y Siddiqui; G Kessie; K Matsushima
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.